



ERIC HOLCOMB, GOVERNOR  
STATE OF INDIANA

*Office of Medicaid Policy and Planning*  
MS 07, 402 W. WASHINGTON STREET, ROOM W382  
INDIANAPOLIS, IN 46204-2739

## MEETING AGENDA AND PUBLIC NOTIFICATION

Therapeutics Committee

February 7, 2025

11:00 A.M. EST

### Hybrid Meeting

Indiana State Government Center South  
Wabash Hall, Conference Rooms 1 & 2  
Virtual Meeting Information Below

1. Call to Order-Chair
2. Preferred Drug List: Therapeutic Class Re-Review - Discussion and Recommendations
3. Preferred Drug List: Therapeutic Class Re-Review
  - a) Respiratory
    - i. Antihistamine-Decongestant Combinations/2<sup>nd</sup> Generation Antihistamines
    - ii. Antiviral Monoclonal Antibody
    - iii. Beta Adrenergics and Corticosteroids
    - iv. Beta Agonists
    - v. Bronchodilator Agents - Beta Adrenergic and Anticholinergic Combinations
    - vi. Leukotriene Receptor Antagonists
    - vii. Nasal Antihistamines/Nasal Anti-Inflammatory Steroids
    - viii. Oral Inhaled Glucocorticoids
    - ix. Pulmonary Antihypertensives
    - x. Respiratory and Allergy Biologics
  - b) Anti-Infectives



- i. Antivirals - Anti-Herpetic Agents
  - ii. Antivirals - Influenza Agents
  - iii. Cephalosporins - 3<sup>rd</sup> Generation
  - iv. Fluoroquinolones
  - v. Hepatitis C Agents
  - vi. Macrolides
  - vii. Ophthalmic Antibiotics
  - viii. Ophthalmic Antibiotics/Corticosteroid Combinations
  - ix. Otic Antibiotics
  - x. Systemic Antifungals
  - xi. Topical Antifungals
  - xii. Topical Antivirals
  - xiii. Topical Antivirals and Anti-Inflammatory Steroid Combinations
  - xiv. Vaginal Antimicrobials
- c) Cardiovascular
- i. Angiotensin-Converting Enzyme (ACE) Inhibitors
  - ii. ACE Inhibitor Combinations
  - iii. Angiotensin II Receptor Antagonists (ARBs)
  - iv. ARB Combinations
  - v. Beta Adrenergic Blockers
  - vi. Beta Adrenergic Blockers with Diuretics
  - vii. Calcium Channel Blockers (CCBs)
  - viii. Miscellaneous Cardiac Agents
- d) Lipotropics
- i. Bile Acid Sequestrants
  - ii. Fibric Acid Derivatives
  - iii. HMG-CoA Reductase Inhibitors
  - iv. Lipotropics
- e) Antimigraine Agents
- f) Electrolyte Depleters
- g) Multiple Sclerosis Agents

h) Targeted Immunomodulators

i) Agents for the Treatment of Opioid Use Disorder  
or Overdose (Off-Cycle Review)

4. Public Comment

5. Other Business

6. Adjourn

---

## Microsoft Teams

[Need help?](#)

[Join the meeting now](#)

Meeting ID: 231 806 313 53

Passcode: Y5X5pU

**Dial in by phone**

[+1 952-222-7450,,548519411#](#) United States, Minneapolis

[Find a local number](#)

Phone conference ID: 548 519 411#

**Join on a video conferencing device**

Tenant key: teams@optum.onpexip.com

Video ID: 115 478 210 21

[More info](#)